Ralf:
I own a bunch of second- and third-tier biotechs that have been getting hammered just like LGND. I've resorted to trading on news; while that's been very successful and countered my rotting long-term portfolio, I try to accumulate the issues without drawing too much attention to them. Given this, I think I'd be foolish to give a list of favorites. I did, in response to a similar question a few days ago, ask Peter Suzman and Jim Silverman to add to a list of those that looked "cheap". The three of us had substantial overlap, and came up with a long list of companies without too much effort. Some comments.....
"Anyone picking OSIP? GENE? ARIA? ARQL? ABSC? (ugh, yech), AXPH?, PCOP?, xxxx?, SIBI?, LGND?, xxxx?, VGINF?, KDUS?, fill in the blank??"
"Amongst others:
I like ARQL, PGNS, MLNM (FYI Lander has sold his last shares--I believe), PDLI, KDUS, ARIA, XNVAY, SIBI, NSTK, GELX, INCY, SNAP, OSIP, AXPH, xxxx is interesting (more insider buying)."
"ARQL, AXPH, PCOP, LGND, VGINF. I'd suggest PCYC if low twenties
are allowed. If we're going for real cheapies, why not NTII? CBMI."
But, then, here's Peter's disclaimer, which was echoed by Jim and which I also proclaim.......
"My trouble with all of these is, although I personally own small
amounts of a few of them, I'd feel awfully funny
recommending them to anyone else. Cheap biotechs are not exactly
market favorites right now, and I suspect its going to be a while
before things turn around."
Cheers! Rick |
